BLAINJECTIONINJECTABLEPriority Review
Approved
Nov 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
ZIIHERA (zanidatamab-hrii) by Jazz Pharmaceuticals is her2-directed antibody interactions [moa]. Approved for bispecific her2-directed antibody [epc]. First approved in 2024.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZIIHERA (zanidatamab-hrii) is a bispecific HER2-directed antibody approved by the FDA on November 20, 2024, for gastroesophageal adenocarcinoma and gastric cancer. It works by simultaneously engaging two distinct epitopes on HER2, enabling dual mechanisms of action including antibody-dependent cellular cytotoxicity and direct growth inhibition. This represents a novel approach to HER2-positive cancers that may overcome resistance to conventional HER2-targeting agents.
Growth
Early-stage growth product with emerging commercial infrastructure; expect expansion of sales, medical affairs, and marketing teams as market adoption accelerates.
Mechanism of Action
HER2-directed Antibody Interactions
Pharmacologic Class:
Bispecific HER2-directed Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Jazz Pharmaceuticals is hiring 7 roles related to this product
Worked on ZIIHERA at Jazz Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.